Treatment options after first-line immunotherapy in metastatic NSCLC.

Expert Review of Anticancer Therapy
Edgardo S Santos

Abstract

Introduction: The recent approvals of checkpoint inhibitors as single agents or in combination with chemotherapy with programmed death ligand 1 expression of < or ≥1% have challenged clinicians when it is time to begin a metastatic lung cancer patient in second-line therapy. The advantages given by immunotherapy over conventional chemotherapy such as improved overall survival and a better toxicity profile make the second-line clinical scenario more difficult for a patient who faces a likely inferior regimen as well as toxicity which may significantly impact the quality of life.Areas covered: Options given today by the National Comprehensive Cancer Network are very limited, and essentially, we go back to conventional cytotoxic agents alone or in combination with biological agents if possible. In this article, we discuss the actual treatment available for this difficult scenario and some of the ongoing trials which aim to address this dilemma.Expert commentary: This is an unmet need in lung cancer management; we need a better understanding of the mechanism of resistance to immunotherapy so we can target them once the patient moves to second-line treatment.

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·L CrinòM Tonato
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nasser HannaPaul A Bunn
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Aug 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio MarchettiFiamma Buttitta
Jun 25, 2013·Expert Opinion on Investigational Drugs·Christian RolfoAntonio Russo
Jan 9, 2014·Radiation Research·Constantinos G Broustas, Howard B Lieberman
Jun 8, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Steven A Rosenberg
Sep 30, 2014·The New England Journal of Medicine·Alice T ShawA John Iafrate
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Jan 21, 2015·The Journal of Experimental Medicine·Thibault VoronMagali Terme
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Feb 3, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Deborah H CharychStephen K Doberstein
Aug 16, 2016·The Journal of Clinical Investigation·Adil I DaudMichael D Rosenblum
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Feb 9, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shiping JiaoMien-Chie Hung
Feb 12, 2017·Cell·Padmanee SharmaAntoni Ribas
Mar 30, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shumei KatoRazelle Kurzrock
Dec 29, 2017·Advances in Experimental Medicine and Biology·Hitomi Sumiyoshi Okuma, Kan Yonemori
Feb 22, 2018·The New England Journal of Medicine·Alexander DrilonDavid M Hyman
Apr 17, 2018·Cancer Discovery·Vivek SubbiahErica K Evans
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
May 19, 2018·Cancer Discovery·Ferdinandos SkoulidisJohn V Heymach
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Enrico VasileAlfredo Falcone
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
C HuismanP E Postmus
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Gini F Fleming
© 2021 Meta ULC. All rights reserved